Home > Browse Research > Life Sciences > Pharmaceuticals > Diseases & Conditions > Osteoporosis

Osteoporosis: market research reports

Osteoporosis is a progressive skeletal disorder that could lead to severe medical problems. Osteoporosis patients are more predisposed to bone fractures resulting from normal daily activities such as walking. Hip fractures are most concerning, as approximately one-third of patients lose mobility and necessitate long-term nursing home care. Moreover, the risk of death among hip fracture patients increases, due to the complications arising from prolonged bed immobilization.

Osteoporosis is characterized by decreased bone mineral density (BMD) and deterioration of the bone microarchitecture, a combination of factors that lead to an increased risk of fracture. Osteoporosis affects hundreds of millions of people worldwide, in developed and undeveloped nations. The prevalence of osteoporosis is projected to increase considerably as the global population ages and life expectancy increases as anticipated. The Office of the Surgeon General in the U.S. warns that osteoporosis may become an epidemic if people do not make the adjustments in nutrition, supplementation, and physical activity necessary to prevent osteoporosis.

The overall cost of osteoporosis fractures and their complications poses a considerable burden for healthcare systems around the world; osteoporosis costs are comparable with those of other major chronic diseases, such as cardiovascular diseases and asthma. In addition, osteoporosis fractures are a major cause of disability and morbidity among older people; an estimated fifth of patients who experience an osteoporotic hip fracture die due to complications within 1 year after the fracture. Drug therapies that are capable of addressing osteoporosis and reducing the risk of fractures could bring economic benefits to governments and healthcare providers and improve the quality of life for osteoporosis patients.

Osteoporosis market research reports and industry analysis

Osteoporosis Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Post Menopausal Osteoporosis – Pipeline Review, H1 2013 4/17/2013 \| published by: Global Markets Direct ... therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis ... \| read more...	$2,000.00
MediPoint: Total Wrist Reconstruction - Current and Future Players 3/31/2013 \| published by: GlobalData ... activities. While it is most prevalent in the developed nations, it is a growing concern in the emerging markets as well. The primary indications that have caused wrist arthritis are osteoarthritis, rheumatoid arthritis and post-traumatic ... \| read more...	$3,500.00
Bone Disorders – Pipeline Review, H1 2013 2/28/2013 \| published by: Global Markets Direct ... Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Bone Disorders - Pipeline Review, Half Year is ... \| read more...	$2,000.00
Osteoporosis – Pipeline Review, H1 2013 2/28/2013 \| published by: Global Markets Direct ... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoporosis. Osteoporosis - Pipeline Review, Half Year is built using data and information ... \| read more...	$2,000.00
PharmaPoint: Osteoporosis - Italy Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - UK Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - France Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022 2/28/2013 \| published by: GlobalData ... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ... \| read more...	$4,995.00
Arthroscopy Devices Market to 2018 - Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Future Growth 1/31/2013 \| published by: GBI Research ... Preference for Minimally Invasive Procedures to Drive Future Growth” looks at the market landscape, competitive landscape, and market trends for the six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy Fluid Management Systems (FMSs), arthroscopy ... \| read more...	$3,500.00
The Osteoporosis Market Outlook to 2021 1/17/2013 \| published by: Datamonitor ... market value as the genericization of key bisphosphonate brands will cause heavy price erosion, leading to a negative growth trend that will continue throughout the forecast period. Features and benefits PDF report filled with analysis ... \| read more...	$4,500.00
The Osteoporosis Market Forecast to 2021 1/17/2013 \| published by: Datamonitor ... market value as the genericization of key bisphosphonate brands will cause heavy price erosion, leading to a negative growth trend that will continue throughout the forecast period. Features and benefits Provides interactive downloads, Excel and ... \| read more...	$8,000.00
Osteoporosis Partnering 2007-2013 1/1/2013 \| published by: Current Partnering ... listed by company A-Z, industry sector, stage of development, technology type The Osteoporosis Partnering 2007-2013 provides understanding and access to the osteoporosis partnering deals and agreements entered into by the worlds leading healthcare companies. The ... \| read more...	$995.00
Osteoarthritis Partnering 2007-2013 1/1/2013 \| published by: Current Partnering ... listed by company A-Z, industry sector, stage of development, technology type The Osteoarthritis Partnering 2007-2013 provides understanding and access to the osteoarthritis partnering deals and agreements entered into by the worlds leading healthcare companies. The ... \| read more...	$995.00
EpiCast Report: Osteoporosis - Epidemiology Forecast to 2022 12/31/2012 \| published by: GlobalData ... make osteoporosis a global health burden, second only to cardiovascular disease (Woolf, 2000). Over the next decade, there will be a 26.8% increase in the prevalent cases of osteoporosis in the nine markets. In 2012, ... \| read more...	$3,995.00
Global Osteoarthritis Drug Pipeline Capsule - 2012 Update 9/10/2012 \| published by: Fore Pharma ... various stages of clinical trials, preclinical research, and drug discovery. This report helps executives track competitors pipeline molecules. The information presented in this report can be used for identifying partners, evaluating opportunities, formulating business development ... \| read more...	$520.00
Osteoporosis Global Clinical Trials Review, H2, 2012 8/27/2012 \| published by: GlobalData ... to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ... \| read more...	$2,500.00
Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019 6/18/2012 \| published by: GlobalData ... The report is an essential source of information and analysis on the global Osteoarthritis Pain Therapeutics market. The report identifies the key trends shaping and driving the global Osteoarthritis Pain Therapeutics market. The report also ... \| read more...	$3,995.00
Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar 6/12/2012 \| published by: GBI Research ... has released its latest research, “Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar”, which provides insights ... \| read more...	$3,500.00
Osteoporosis Therapeutics 5/1/2012 \| published by: Global Industry Analysts ... Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key ... \| read more...	$4,500.00

< prev 1 2 3 4 5 next >